Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.
Published in Molecular therapy : the journal of the American Society of Gene Therapy • Feb 7, 2018
Authors:,,
Annette B Vogel
Laura Lambert
Ekaterina Kinnear
Abstract
New vaccine platforms are needed to address the time gap between pathogen emergence and vaccine licensure. RNA-based vaccines are an attractive candidate for this role: they are safe, are produced cell free, and can be rapidly generated in response to pathogen emergence. Two RNA vaccine platforms ar...